-

Shareholder Alert: Robbins LLP Announces It Is Investigating Mohawk Industries, Inc. (MHK) for Misleading Shareholders

SAN DIEGO & CALHOUN, Ga.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Mohawk Industries, Inc. (NYSE: MHK) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Mohawk Industries designs, manufactures, sources, distributes, and markets flooring products for residential and commercial spaces worldwide.

If you suffered a loss as a result of Mohawk's misconduct, click here.

Mohawk Industries, Inc. (MHK) Fails to Meet Company Guidance

Beginning in April 2017, Mohawk touted its purported "growing demand" for its conventional flooring products and continued to highlight its sales growth throughout the relevant period. Then, on July 25, 2019, after repeatedly reporting financial results that missed analysts' estimates and the Company's guidance range, Mohawk revealed sales in its Flooring NA segment were down 7% because "lower demand" for certain conventional flooring products had created excess inventory that impacted Mohawk's sales and margins. On this news, Mohawk's stock dropped $27.76, nearly 18%, to close at $128.84. The stock has yet to recover. It appears that Mohawk had been channel stuffing by causing its distributors to take on surpluses of Conventional Flooring Products that were greater than demand to make Mohawk's sales growth and financial performance appear better than they were.

Mohawk Industries, Inc. (MHK) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Mohawk settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:MHK

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom